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In this issue of Neuron, Kim et al. and Enomoto et al. show that DISC1 plays a key role in regulating postnatal
brain development though interaction with Girdin. Girdin in turn regulates AKT signaling. Thus, another facet
of the role of DISC1 is established, shedding more light on fundamental brain processes and the develop-
mental basis of major psychiatric disorders.DISC1 in Schizophrenia,
Protein-Protein Interaction,
and Neurodevelopment
DISC1 was discovered as a novel gene at
the breakpoint of a balanced (1;11) trans-
location that segregates with schizo-
phrenia, bipolar disorder, and recurrent
major depression in a large Scottish
family (reviewed in Chubb et al., 2008).
This discovery was both surprising and
insightful. Here was a single genetic event
that could give rise, with high penetrance
(the majority of carriers are affected), to
a range of psychiatric disorders that tran-
scended traditional diagnostic bound-
aries, challenging many strongly held
precepts about the genetic etiology of
psychotic and mood disorders. Subse-
quent genetic studies have found sup-
porting evidence for DISC1 as a general-
ized risk factor in a significant proportion
of cases and have extended the diag-
nostic boundaries of influence to include
autism spectrum disorder and cognitive
aging (reviewed in Chubb et al., 2008).
Upon discovery, and showing no
obvious similarity to other known genes
or proteins, the function of DISC1 was far
from clear. De novo biochemical and
expression studies established that
DISC1 was a multifunctional, neurodeve-
lopmentally regulated scaffold protein,
which when mutated in the mouse
gave rise to developmental, behavioral,
and pharmacological phenotypes that
modeled important aspects of the human
conditions (Clapcote et al., 2007; re-
viewed inChubbet al., 2008). This scaffold
function resolves the genetics paradox—
the multiple proteins shown to interact
with DISC1 are enriched for proteinsknown to have a role in neurodevelop-
ment, neurosignaling, cytoskeletal and
centromeric function, and the synapse,
thus having the potential to simulta-
neously affect a wide range of plausible
risk processes in susceptibility. And
indeed, several of theseDISC1 interactors
turn out to be codependent or indepen-
dent genetic risk factors (reviewed in
Chubb et al., 2008).
The question now becomes: which of
these many potential interactors matter
most, and at what point in development
and at what location in the brain? Previ-
ously, Duan et al. (2007) used an elegant,
retrovirally mediated, single-cell RNAi
strategy to selectively suppress mouse
Disc1 expression in vivo in differentiating
hippocampal neuronal precursor cells.
They made the striking observation that
Disc1 suppression in neuronal precursors
resulted in overmigration, aberrant in-
tegration, and misfiring. But by what
means? The papers by Kim et al. (2009)
and Enomoto et al. (2009) in this issue of
Neuron demonstrate that the critical func-
tion of DISC1 in postnatal hippocampal
neurogenesis is mediated in large part
by interaction with KIAA1212, known also
and more evocatively as Girdin (Girders
of actin filaments). Kim et al. (2009) fur-
ther demonstrate that this interaction
suppresses AKT signaling and, remark-
ably, that the gross effects of Disc1
suppression can be largely rescued by ra-
pamycin,which inhibitsmTOR, aneffector
pathway activated by AKT signaling.
Girdin Gets In on the AKT
Enomoto and colleagues had previously
reported that AKT1, a key serine/threo-Neuron 63, Snine-specific kinase with multiple
signaling properties, regulates actin orga-
nization and cell motility via Girdin, which
directly binds actin at the leading edge
of migrating cells. Drawing upon the
evidence from a yeast two-hybrid screen
that Girdin/KIAA1212 is a putative DISC1
interactor (Camargo et al., 2007), both
Enomoto et al. (2009) and Kim et al.
(2009) demonstrate physiological inter-
action between DISC1 and Girdin, albeit
with some disagreement over the DISC1
interaction domains. Enomoto et al.
(2009) show that in postnatal rodent brain
Girdin is predominantly expressed in the
dentate gyrus and pyramidal cell layers
CA1 andCA3 of the hippocampus, mirror-
ing DISC1 expression. Girdin affects
angiogenesis and knockout mice do not
survive into adulthood, but examination
of early postnatal brain demonstrated
a profound effect on development of the
dentate gyrus. Uniquely in the brain, the
dentate gyrus is formed postnatally and
neurogenesis is continual. Examination
of Girdin-deficient mice and experimental
suppression of Girdin by retroviral-medi-
ated siRNA demonstrated that Girdin
regulates the migration and positioning
of newborn dentate gyrus cells (Eno-
moto et al., 2009). Thus, in many, but
not quite all respects, Girdin suppres-
sion mimics the effects of Disc1
suppression in adult neuronal progenitor
cells, as reported previously by Duan
et al. (2007). Enomoto et al. (2009) also
reported that Disc1 suppression was
associated with reduced Girdin im-
munoreactive protein at the growth
cone, suggesting that DISC1 normally
stabilizes and anchors Girdin there.eptember 24, 2009 ª2009 Elsevier Inc. 711
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report a similar phenotype to Disc1
suppression upon overexpression of
Girdin, but this perhaps indicates that
both the balance of DISC1 interactome
expression and the resultant stoichiom-
etry of interactors, as well as the precise
developmental timing of expression, is
important.
A last point of apparent disagreement
between the two studies relates to the
role of AKT signaling. Enomoto et al.
(2009) show that expression of a domi-
nantly acting form of AKT does, as ex-
pected, abolish neuronal polarity, but
this could not rescue the axonal defect
inGirdin-suppressed neurons. Consistent
with this, they report that the level of
phosphorylated, active AKT in Girdin
knockout mice is unaltered, arguing that
Girdin acts downstream of AKT. By
contrast, Kim et al. (2009) present multiple
strands of evidence that DISC1 interac-
tion with Girdin does indeed regulate
AKT activity, as measured by phosphory-
lated AKT at Ser473, and by phosphoryla-
tion of S6, a well-characterized down-
stream target of mammalian target of
rapamycin (mTOR)-AKT. Using the retro-
viral infection strategy to target pro-
liferating progenitor cells in the dentate
gyrus, they also showed that phenotypes
of Disc1 suppression, namely increased
soma size and number of primary
dendrites, were mimicked by three strate-
gies designed to activate AKT signaling:
(1) expression of constitutively active
AKT, (2) suppression of PTEN, a known
suppressor of AKT activation, and (3)
overexpression of Girdin. Moreover, they
show that Girdin activity is modulated by
DISC1 and, remarkably, that the effect of
Disc1 suppression in dentate gyrus cells
could be rescued by rapamycin. Rapamy-
cin is the eponymous inhibitor of the
mTOR function of AKT. Rapamycin is a
potent immunosuppressant, so it is un-
likely to be appropriate for chronic human
use, but interestingly both the synaptic
plasticity deficit and the cognitive be-
havior deficit in a mouse model of tu-
berous sclerosis were reportedly rescued
after brief treatment with rapamycin
(Ehninger et al., 2008).
AKT, GSK3b, and Schizophrenia
The genetic evidence for AKT being a risk
factor for schizophrenia is modest by712 Neuron 63, September 24, 2009 ª2009comparison to DISC1, but there is
a growing body of evidence from human
and mouse studies that the AKT pathway
may indeed be important (reviewed by
Arguello and Gogos, 2008). Genetic
variants in AKT1 have been reported to
be associated with schizophrenia. AKT1
activity and AKT-dependent phos-
phorylation of GSK3b is decreased in
postmortem schizophrenic brains. Akt1
knockout mice show impaired prepulse
inhibition of the startle response, a cor-
ollary of the altered salience typifying
schizophrenia, which is exacerbated by
amphetamine (which can induce psy-
chosis on chronic exposure in humans)
and responds poorly to DRD2 (but not
DRD1) agonists, the target of most cur-
rent antipsychotic drugs. By contrast,
both typical and atypical antipsychotics
enhance AKT signaling by activating
AKT or by increasing phosphorylation of
GSK3b.
Mao et al. (2009) recently identified
GSK3b as a novel DISC1 interactor,
bringing the wnt pathway and b-catenin
neurosignaling firmly to the fore. GSK3b
is inhibited by both AKT signaling and by
DISC1. It is a known target for the widely
used mood stabilizer Lithium Chloride.
Mao et al. (2009) further reported that
administration of the GSK3b-specific
inhibitor SB216763 could rescue the
behavioral effects of lentivirally induced
Disc1 suppression in the adult dentate
gyrus. Interestingly, Kim et al. (2009) failed
to see a rescuing effect of SB216763
on Disc1-suppressed newborn dentate
granule cells. This suggests that DISC1
(and indeed different DISC1 interactors)
may have different premitotic and postmi-
totic effects on adult neurogenesis. When
all the evidence is taken together, we now
have a tantalizing picture of how DISC1,
through AKT, GSK3b, and other protein
partners yet to be fully described, may
regulate both neurodevelopment and
neurotransmission, two core yet often
opposed concepts in schizophrenia
etiology. If the rather remarkable effects
of rapamycin reported by Kim et al.
(2009) and of SB216763 reported by Mao
et al. (2009) are positive portents of future
therapeutic strategies, it will nevertheless
be critical to determine exactly which
aspects of the DISC1 pathway phenotype
must be corrected, andwhen, duringbrain
development.Elsevier Inc.What Else and What Next?
The structure of DISC1 is not yet solved,
but we know that DISC1 comprises
a highly disordered N-terminal head
domain and a C-terminal tail with multiple
coiled-coil domains (reviewed in Chubb
et al., 2008). This protein is built for
protein-protein interaction. Millar et al.
(2005) previously reported a genetic and
biochemical link between DISC1 and
PDE4B in modulating cAMP signaling
through multiple binding sites specific to
different isoforms of PDE4 (Murdoch
et al., 2007). Mice display distinct behav-
iors and pharmacological responses of
a schizophrenic-like or mood disorder
nature depending upon which PDE4B
binding domain is mutated (Clapcote
et al., 2007). Intriguingly, the binding
domains for PDE4, GSK3b, and now Gir-
din at least partially overlap. Both DISC1
and Girdin dimerize and both bind
NDEL1, which in turn binds NDE1 and
thus LIS1, yet another key protein in brain
development. DISC1 forms higher-order
multimers, a process that appears to alter
the binding of NDEL1 and is sensitive to
polymorphic variation at the Ser704Cys
position (Leliveld et al., 2009). This poly-
morphism has been previously related by
fMRI and working memory tasks to differ-
ential hippocampal engagement in normal
human subjects, and also to altered brain
expression of DISC1 partners (reviewed
in Chubb et al., 2008). Variants of DISC1,
PDE4B, PDE4D, and NDE1 are genetic
risk factors in their own right (reviewed in
Chubb et al., 2008) and are also transcrip-
tionalmodulators of cytoskeletal, synapto-
genic, neurodevelopmental, and sensory
perception proteins (Hennah and Por-
teous, 2009). This set of proteins is signifi-
cantly enriched for current targets of
psychiatric drug development (Hennah
and Porteous, 2009). When considering
what DISC1 interacts with, and where
and when it does so, it is important also
to take account of the growing evidence
for multiple transcripts and protein iso-
forms of DISC1 and their developmental
regulation (reviewed in Chubb et al.,
2008). This will have a direct bearing
upon the capacity for DISC1 to self-asso-
ciate and to bind potential interactors.
Self-evidently, considering DISC1 interac-
tions only in pairwise fashion is bound to
oversimplify and potentially deceive.
Defining the DISC1 proteome by cell type
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natal development and in the adult brain
may be necessary for a full understand-
ing of the multiplicity of DISC1 functions,
how these relate to psychopathology,
and what that means for treatment
strategies.
The DISC1 Proteome: A Suite
in G Minor?
The DISC1 pathway is relevant to many of
the saddest and most tragic human
conditions—schizophrenia, bipolar dis-
order, and major depression at least,
and possibly autism too. The emerging
picture is of DISC1 as the orchestrator of
a suite of protein-protein interactions
harmonized in time and space. Extending
the musical analogy to schizophrenia, if
the conductor is off tempo, no matter
how able the symphony of brain players,
the net result will be off key. And even if
the DISC1 conductor is on tempo, if any
of the key players are out of tune, then
the brain performance may be perceived
as similarly discordant.
It now becomes critical to establish the
biophysical state of the DISC1 complex in
both time and place, the valency of
protein-interaction, and the extent to
which this is independent, cooperative,
or competitive. We speculate that the
mechanism by which the DISC1 interac-
tome regulates pathways of action is to
sequester and compartmentalize sig-
naling pathways on a cell-by-cell andcell compartment-by cell compartment
basis. In this model, we are replacing the
conventional depiction of linear path-
ways, feedback loops, and ‘‘upstream/
downstream’’ (see for example Figure 7
in Kim et al., 2009) with the concept that
the DISC1 complex is the pathway,
whether in the nucleus, at the growth
cone, the centrosome, the mitochondria,
or the presynaptic or postsynaptic
density. Each pathway or suite is defined
by local and locally determined isoforms,
interactions, cAMP concentrations, and
phosphorylation states. To test and refine
this will require an even finer level of
cellular molecular anatomy, but it is
around this concept that we would seek
and expect to devise molecular therapies
that were both effective and safe.
Ongoing structure-function analyses will
be aided by current, major efforts now
underway to define causal clinical vari-
ants in the DISC1 pathway through
genomic resequencing. Major challenges
remain, but remarkable progress has
been made and further progress toward
understanding and intervention will surely
follow.
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